Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2024, to be held in Houston, TX from June 1 through June 5, 2024.
| WASHINGTON, May 29, 2024 /PRNewswire/ -- Vanda Pharmaceuticals, Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2024, to be held in Houston, TX from June 1 through June 5, 2024.
The following will be presented: June 4, 2024 Presentation Title: “Drug Screening and CRISPR/Cas9 Screening of HCN Channels” Presentation Title: “Melanopsin Crispants in Zebrafish Display Difference in Sleep Latency” Presentation Title: “Genetic Variants Associated with Dim Light Melatonin Onset in a Delayed Sleep-Wake Phase Disorder Cohort” Presentation Title: “Genetic variants associated with TST and LPS in insomnia patients: whole genome sequencing study” For more information on SLEEP 2024, please refer to https://www.sleepmeeting.org/ About Vanda Pharmaceuticals Inc. Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma. Corporate Contact: Jim Golden / Jack Kelleher / Dan Moore
SOURCE Vanda Pharmaceuticals Inc. | ||
Company Codes: NASDAQ-NMS:VNDA |
View original content to download multimedia:
